Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA crosslinking via oxaliplatin refers to the formation of covalent bonds between DNA strands or within a single strand, induced by the platinum-based chemotherapeutic agent oxaliplatin. This process disrupts essential cellular functions such as DNA replication and transcription, ultimately leading to cell death. Oxaliplatin primarily induces intrastrand crosslinks, especially between adjacent guanine bases, but also forms interstrand crosslinks and adducts. The platinum atom in oxaliplatin binds mainly at the N7 position of guanine residues. These adducts bend the double helix, inhibiting replication and transcription. Nucleotide excision repair is primarily responsible for removing oxaliplatin-induced lesions. The cytotoxic effect resulting from this target mechanism underpins the clinical use of oxaliplatin against cancers.
Formation of DNA intra- and inter-strand crosslinks, primarily at guanine residues, leading to inhibition of DNA replication and transcription and subsequent cell death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Crosslinking via Oxaliplatin.